Matching articles for "sildenafil"
Issue 1754 · May 11, 2026 Free
In Brief: Vybrique — Sildenafil Oral Film for Erectile Dysfunction

The FDA has approved Vybrique (IBSA), an oral film formulation of the phosphodiesterase type 5 (PDE5) inhibitor sildenafil, for treatment of erectile dysfunction (ED). Sildenafil oral tablets ( Viagra , and…

Med Lett Drugs Ther. 2026 May 11; 68(1754):78-9 doi:10.58347/tml.2026.1754e
The FDA has approved Vybrique (IBSA), an oral film formulation of the phosphodiesterase type 5 (PDE5) inhibitor sildenafil, for treatment of erectile dysfunction (ED). Sildenafil oral tablets ( Viagra , and generics) have been available since 1998. The manufacturer is promoting the new product as a "discreet, on-the-go" option that can be taken without water.
Issue 1715 · November 11, 2024
Eroxon — An OTC Gel for Erectile Dysfunction

The FDA has authorized over-the-counter (OTC) sale of a nonmedicated alcohol-based gel ( Eroxon – Futura) for treatment of erectile dysfunction (ED) in males ≥22 years old. Eroxon is the only FDA-approved…

Med Lett Drugs Ther. 2024 Nov 11; 66(1715):181-2 doi:10.58347/tml.2024.1715c
The FDA has authorized over-the-counter (OTC) sale of a nonmedicated alcohol-based gel ( Eroxon – Futura) for treatment of erectile dysfunction (ED) in males ≥22 years old. Eroxon is the only FDA-approved OTC and topical treatment for erectile dysfunction. It is also available in the UK and the EU.
Issue 1702 · May 13, 2024
Sotatercept (Winrevair) for Pulmonary Arterial Hypertension

The FDA has approved sotatercept-csrk ( Winrevair – Merck), a first-in-class activin signaling inhibitor, to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical…

Med Lett Drugs Ther. 2024 May 13; 66(1702):73-5 doi:10.58347/tml.2024.1702a
The FDA has approved sotatercept-csrk ( Winrevair – Merck), a first-in-class activin signaling inhibitor, to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events in adults with WHO Group 1 pulmonary arterial hypertension (PAH).
Issue 1690 · November 27, 2023
Shockwave Therapy for Erectile Dysfunction

Low-intensity extracorporeal shockwave therapy similar to that used to fragment kidney stones or gallstones is a new option for treatment of erectile dysfunction that is now being advertised extensively in the…

Med Lett Drugs Ther. 2023 Nov 27; 65(1690):190-1 doi:10.58347/tml.2023.1690d
Low-intensity extracorporeal shockwave therapy similar to that used to fragment kidney stones or gallstones is a new option for treatment of erectile dysfunction that is now being advertised extensively in the US. It has not been approved by the FDA for treatment of erectile dysfunction.
Issue 1509 · December 5, 2016
Sublingual Nitroglycerin Powder (GoNitro)

The FDA has approved a sublingual powder formulation of nitroglycerin ( GoNitro – Espero) for prevention or acute relief of an attack of angina pectoris. It is the first powder formulation of nitroglycerin…

Med Lett Drugs Ther. 2016 Dec 5; 58(1509):156-7
The FDA has approved a sublingual powder formulation of nitroglycerin ( GoNitro – Espero) for prevention or acute relief of an attack of angina pectoris. It is the first powder formulation of nitroglycerin to become available in the US. Most patients with angina use sublingual nitroglycerin tablets ( Nitrostat , and generics). Translingual spray formulations of nitroglycerin ( NitroMist , Nitrolingual Pumpspray , and generics) are also available.
Issue 1488 · February 15, 2016
Selexipag (Uptravi) for Pulmonary Arterial Hypertension

The FDA has approved selexipag ( Uptravi – Actelion), an oral selective prostacyclin IP receptor agonist, for treatment of pulmonary arterial hypertension (PAH). Treprostinil (Orenitram) , an oral…

Med Lett Drugs Ther. 2016 Feb 15; 58(1488):21-3
The FDA has approved selexipag ( Uptravi – Actelion), an oral selective prostacyclin IP receptor agonist, for treatment of pulmonary arterial hypertension (PAH). Treprostinil (Orenitram) , an oral prostacyclin analog, was approved earlier for this indication.
Issue 1485 · January 4, 2016
Ambrisentan (Letairis) and Tadalafil (Adcirca) for Pulmonary Arterial Hypertension

The FDA has approved the use of ambrisentan (Letairis) and tadalafil (Adcirca) together for treatment of pulmonary arterial hypertension (PAH). It is the first 2-drug regimen to be approved for this indication.

Med Lett Drugs Ther. 2016 Jan 4; 58(1485):2-4
The FDA has approved the use of ambrisentan (Letairis) and tadalafil (Adcirca) together for treatment of pulmonary arterial hypertension (PAH). It is the first 2-drug regimen to be approved for this indication.
Issue 1468 · May 11, 2015
Testosterone Nasal Gel (Natesto) for Hypogonadism

The FDA has approved an intranasal gel formulation of testosterone ( Natesto – Trimel/Endo) for replacement therapy in men with hypogonadism. Packaged in a metered-dose pump, Natesto is the first intranasal…

Med Lett Drugs Ther. 2015 May 11; 57(1468):73-4
The FDA has approved an intranasal gel formulation of testosterone ( Natesto – Trimel/Endo) for replacement therapy in men with hypogonadism. Packaged in a metered-dose pump, Natesto is the first intranasal testosterone to become available in the US. Like other testosterone products, it is classified as a schedule III controlled substance. The FDA recently cautioned against using testosterone to treat low testosterone levels solely due to aging because the benefits and safety of such use have not been established, and there is a possible increased risk of myocardial infarction (MI) and stroke.
Issue 1461 · February 2, 2015
A 4-Drug Combination (Viekira Pak) for Hepatitis C

The FDA has approved Viekira Pak (Abbvie), a fixed-dose combination of two new direct-acting antiviral agents (ombitasvir, paritaprevir) with the pharmacologic enhancer ritonavir in one tablet, co-packaged…

Med Lett Drugs Ther. 2015 Feb 2; 57(1461):15-7
The FDA has approved Viekira Pak (Abbvie), a fixed-dose combination of two new direct-acting antiviral agents (ombitasvir, paritaprevir) with the pharmacologic enhancer ritonavir in one tablet, co-packaged with a third new direct-acting antiviral agent (dasabuvir) in a second tablet, for oral treatment of chronic hepatitis C virus (HCV) genotype 1 infection. Genotype 1 is responsible for 70-80% of HCV infections in the US.
Issue 1460 · January 19, 2015
Drugs for Chronic Heart Failure

Heart failure is usually associated with left ventricular dysfunction. According to recent guidelines, patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with…

Med Lett Drugs Ther. 2015 Jan 19; 57(1460):9-13
Heart failure is usually associated with left ventricular dysfunction. According to recent guidelines, patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) or systolic heart failure. Patients with a LVEF ≥50% and symptoms of heart failure are considered to have heart failure with preserved ejection fraction (HFpEF) or diastolic heart failure; there is little evidence that drug treatment improves clinical outcomes in these patients. The treatment of acute heart failure is not included here.
Issue 1442 · May 12, 2014
Avanafil (Stendra) - Another PDE5 Inhibitor for Erectile Dysfunction

The FDA has approved avanafil ( Stendra – Vivus), an oral phosphodiesterase type-5 (PDE5) inhibitor, for treatment of erectile dysfunction. It is the fifth PDE5 inhibitor to be approved for this indication.…

Med Lett Drugs Ther. 2014 May 12; 56(1442):37-8
The FDA has approved avanafil ( Stendra – Vivus), an oral phosphodiesterase type-5 (PDE5) inhibitor, for treatment of erectile dysfunction. It is the fifth PDE5 inhibitor to be approved for this indication. Advertisements on Stendra ’s website imply that it has a faster onset of action than other PDE5 inhibitors.
Issue 1437 · March 3, 2014 Free
In Brief: Testosterone and Cardiovascular Risk

Prompted by the recent publication of 2 retrospective studies, the FDA has announced that it is investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products. 1 The…

Med Lett Drugs Ther. 2014 Mar 3; 56(1437):17
Prompted by the recent publication of 2 retrospective studies, the FDA has announced that it is investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products. 1 The first study examined the records of 8709 men with low testosterone levels (<300 ng/dL) who underwent coronary angiography between 2005 and 2011; 1223 of these men started testosterone therapy after a median of 531 days following coronary angiography. Three years after coronary angiography, the Kaplan-Meier estimated cumulative percentages of men who died or had a myocardial infarction (MI) or ischemic stroke were 26% of those treated with testosterone and 20% of those who were not treated with the hormone, a hazard ratio of 1.29 (95% CI 1.04-1.58; P=0.02). 2 The second study compared the rate of nonfatal MI during the 90 days after filling a prescription with the rate in the prior year in 56,000 men given a prescription for testosterone and in 167,000 given a phosphodiesterase type 5 inhibitor (sildenafil [Viagra] or tadalafil [Cialis] ). In the testosterone group as a whole, the post/pre-prescription rate ratio was 1.36, but in men ≥65 years old it was 2.19 and in younger men with a history of heart disease it was 2.90. In men who received a prescription for sildenafil or tadalafil, the rate ratio was 1.08 for all ages, 1.15 for those ≥65 years old, and 1.40 for younger men with a history of heart disease. 3 A recent meta-analysis of randomized, placebo-controlled trials of testosterone therapy also found an increased risk of cardiovascular-related events in men treated with the hormone (odds ratio [OR] 1.54; 95% CI 1.09-2.18); an analysis by funding source found that the risk was greater in trials not funded by the pharmaceutical industry (OR 2.06 vs. 0.89). 4 1. FDA Drug Safety Communication January 31, 2014: FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. Available at www.fda.gov. Accessed February 24, 2014. 2. R Vigen et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310:1829. 3. WD Finkle et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014; 9:e85805. 4. L Xu et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013; 11:108. Download complete U.S. English article
Issue 1437 · March 3, 2014
Riociguat (Adempas) for Pulmonary Hypertension

The FDA has approved the sGC stimulator riociguat (rye" oh sig' ue at; Adempas – Bayer) for oral treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)…

Med Lett Drugs Ther. 2014 Mar 3; 56(1437):17-9
The FDA has approved the sGC stimulator riociguat (rye" oh sig' ue at; Adempas – Bayer) for oral treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) following surgery or when surgery is not an option. It is the first drug to be approved for treatment of CTEPH.
Issue 1436 · February 17, 2014
Macitentan (Opsumit) for Pulmonary Arterial Hypertension

The FDA has approved macitentan (ma" si ten' tan; Opsumit – Actelion), for oral treatment of pulmonary arterial hypertension (PAH). Macitentan is the second nonselective endothelin receptor antagonist…

Med Lett Drugs Ther. 2014 Feb 17; 56(1436):15-6
The FDA has approved macitentan (ma" si ten' tan; Opsumit – Actelion), for oral treatment of pulmonary arterial hypertension (PAH). Macitentan is the second nonselective endothelin receptor antagonist approved for PAH. It is a derivative of bosentan (Tracleer) , which is also manufactured by Actelion, and is scheduled to become available generically in 2015. Riociguat (Adempas) , another new drug for this indication, will be reviewed in a future issue. Volibris
Issue 1383 · February 6, 2012
PDE5 Inhibitors for Erectile Dysfunction

Sildenafil (Viagra) , tadalafil (Cialis) and vardenafil (Levitra, Staxyn) have become the standard treatment for erectile dysfunction. Head-to-head comparisons of these agents are still lacking, but some…

Med Lett Drugs Ther. 2012 Feb 6; 54(1383):10-1
Sildenafil (Viagra) , tadalafil (Cialis) and vardenafil (Levitra, Staxyn) have become the standard treatment for erectile dysfunction. Head-to-head comparisons of these agents are still lacking, but some differences between them and new recommendations for their dosing (see Table 2) are worth noting.
Issue 1377 · November 14, 2011
Tadalafil (Cialis) for Signs and Symptoms of Benign Prostatic Hyperplasia

The FDA has approved the use of the phosphodiesterase-5 (PDE-5) inhibitor tadalafil ( Cialis – Lilly) for treatment of signs and symptoms of benign prostatic hyperplasia (BPH) in men with or without erectile…

Med Lett Drugs Ther. 2011 Nov 14; 53(1377):89-90
The FDA has approved the use of the phosphodiesterase-5 (PDE-5) inhibitor tadalafil ( Cialis – Lilly) for treatment of signs and symptoms of benign prostatic hyperplasia (BPH) in men with or without erectile dysfunction. Tadalafil is approved for use under another brand name (Adcirca) for treatment of pulmonary arterial hypertension. The other PDE-5 inhibitors available in the US for treatment of erectile dysfunction (sildenafil [Viagra] ; vardenafil [Levitra] ) have also been reported to be effective for treatment of BPH signs and symptoms, but have not been approved for this indication by the FDA.
Issue 1353 · December 13, 2010
Drugs for Female Sexual Dysfunction

Sexual complaints related to desire, arousal, orgasm and painful intercourse are common in women. Since the last Medical Letter article on this subject, some new information has become available.

Med Lett Drugs Ther. 2010 Dec 13; 52(1353):100-2
Sexual complaints related to desire, arousal, orgasm and painful intercourse are common in women. Since the last Medical Letter article on this subject, some new information has become available.
Issue 1324 · November 2, 2009
Tadalafil (Adcirca) for Pulmonary Arterial Hypertension

The FDA has approved use of tadalafil ( Adcirca - Lilly/United Therapeutics) for treatment of pulmonary arterial hypertension (PAH).

Med Lett Drugs Ther. 2009 Nov 2; 51(1324):87-8
The FDA has approved use of tadalafil ( Adcirca - Lilly/United Therapeutics) for treatment of pulmonary arterial hypertension (PAH).
Issue 1301 · December 15, 2008 Free
Drugs That May Cause Psychiatric Symptoms

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness,…

Med Lett Drugs Ther. 2008 Dec 15; 50(1301):100-3
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression. Click here to view the free full article.
Issue 1283 · April 7, 2008
Tadalafil (Cialis) Once a Day for Erectile Dysfunction

The phosphodiesterase type 5 (PDE5) inhibitor tadalafil ( Cialis - Lilly) is now being promoted for once daily treatment of erectile dysfunction. Tadalafil differs from sildenafil ( Viagra ) and vardenafil…

Med Lett Drugs Ther. 2008 Apr 7; 50(1283):27-8
The phosphodiesterase type 5 (PDE5) inhibitor tadalafil ( Cialis - Lilly) is now being promoted for once daily treatment of erectile dysfunction. Tadalafil differs from sildenafil ( Viagra ) and vardenafil (Levitra) , the other PDE5 inhibitors marketed for erectile dysfunction in the US, in having a much longer duration of action.
Issue 1279 · February 11, 2008 Free
In Brief: Herbal Warning

The FDA recently advised health care professionals and consumers not to use a number of dietary supplements found to contain the phosphodiesterase-5 inhibitor sildenafil ( Viagra ) or an analog of the drug…

Med Lett Drugs Ther. 2008 Feb 11; 50(1279):9
The FDA recently advised health care professionals and consumers not to use a number of dietary supplements found to contain the phosphodiesterase-5 inhibitor sildenafil ( Viagra ) or an analog of the drug (www.fda.gov) . Although the effects of sildenafil may be noticeable (in men), the presence of other, possibly more toxic adulterants in dietary supplements may be more difficult or impossible to detect. Other drugs previously found in dietary supplements have included lovastatin ( Mevacor , and others), estrogen, alprazolam ( Xanax , and others), indomethacin ( Indocin , and others) and warfarin ( Coumadin , and others). Aristolochic acid in Chinese herbal weight loss products caused acute renal failure in about 100 women in Belgium; at least 70 of them required dialysis or transplantation, and at least 18 developed urothelial cancer ( Med Lett Drugs Ther 2002; 44:84 ). Dietary supplements do not require FDA approval before marketing. The agency does have the power to remove mislabeled or adulterated products from store shelves, but the burden of discovery and proof is entirely on the government. Download U.S. English
Issue 1272 · October 22, 2007
Ambrisentan (Letairis) for Pulmonary Arterial Hypertension

Ambrisentan ( Letairis - Gilead), a selective endothelin type A (ET A ) receptor antagonist, has been approved by the FDA for treatment of symptomatic patients (WHO class II or III) with pulmonary arterial…

Med Lett Drugs Ther. 2007 Oct 22; 49(1272):87-8
Ambrisentan ( Letairis - Gilead), a selective endothelin type A (ET A ) receptor antagonist, has been approved by the FDA for treatment of symptomatic patients (WHO class II or III) with pulmonary arterial hypertension (PAH).
Issue 1259 · April 23, 2007
Drugs for Female Sexual Dysfunction

Sexual complaints related to desire, arousal, orgasm and pain are common in women. No drugs are approved by the FDA for any of these indications, but many are used off-label.

Med Lett Drugs Ther. 2007 Apr 23; 49(1259):33-5
Sexual complaints related to desire, arousal, orgasm and pain are common in women. No drugs are approved by the FDA for any of these indications, but many are used off-label.
Issue 1218 · September 28, 2005
BiDil for Heart Failure

BiDil (NitroMed), a fixed-dose combination of isosorbide dinitrate and hydralazine, was approved by the FDA for adjunctive use in the treatment of heart failure in black patients.Both drugs are oral…

Med Lett Drugs Ther. 2005 Sep 28; 47(1218):77-8
BiDil (NitroMed), a fixed-dose combination of isosorbide dinitrate and hydralazine, was approved by the FDA for adjunctive use in the treatment of heart failure in black patients.Both drugs are oral vasodilators that have been used together off-label for many years to treat heart failure in patients not responding to other drugs.
Issue 1215 · August 15, 2005
Sildenafil (Revatio) for Pulmonary Arterial Hypertension

The Medical Letter reported last year that sildenafil ( Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now…

Med Lett Drugs Ther. 2005 Aug 15; 47(1215):65-7
The Medical Letter reported last year that sildenafil ( Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now the results of such a study are about to be published, and the drug has been approved by the FDA for this indication under the trade name Revatio .
Issue 1212 · July 4, 2005
CYP3A and Drug Interactions

Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in…

Med Lett Drugs Ther. 2005 Jul 4; 47(1212):54-5
Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the metabolism of more than 50 percent of currently prescribed drugs.2 CYP3A4, which is more abundantly expressed than CYP3A5, accounts for most CYP3A activity in vivo .
Issue 1211 · June 20, 2005
Viagra and Loss of Vision

The FDA recently announced that it was investigating 38 reports of loss of vision in men who took sildenafil (Viagra) , which has been used to treat erectile dysfunction since 1998.

Med Lett Drugs Ther. 2005 Jun 20; 47(1211):49
The FDA recently announced that it was investigating 38 reports of loss of vision in men who took sildenafil (Viagra) , which has been used to treat erectile dysfunction since 1998.
Issue 1195 · November 8, 2004
Tablet Splitting

Breaking drug tablets in half is a common practice. In some cases, a lower drug dose may be as effective as a higher one, with fewer adverse effects. Sometimes tablets are split to achieve an intermediate dose…

Med Lett Drugs Ther. 2004 Nov 8; 46(1195):89-91
Breaking drug tablets in half is a common practice. In some cases, a lower drug dose may be as effective as a higher one, with fewer adverse effects. Sometimes tablets are split to achieve an intermediate dose between marketed strengths. When 2 tablet sizes cost the same, as they often do, splitting the larger size saves money. Is this a reasonable practice?
Issue 1177 · March 1, 2004
Sildenafil for Pulmonary Hypertension

Several recent case reports suggest that oral sildenafil may be effective for treatment of pulmonary arterial hypertension (PAH). Sildenafil is currently marketed as Viagra for treatment of erectile…

Med Lett Drugs Ther. 2004 Mar 1; 46(1177):18-9
Several recent case reports suggest that oral sildenafil may be effective for treatment of pulmonary arterial hypertension (PAH). Sildenafil is currently marketed as Viagra for treatment of erectile dysfunction ( Medical Letter 1998; 40:51 ).
Issue 1173 · January 5, 2004
Drug Interactions with Grapefruit Juice

The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice…

Med Lett Drugs Ther. 2004 Jan 5; 46(1173):2-4
The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice used to disguise the taste of ethanol resulted in higher than expected serum concentrations of felodipine (DG Bailey et al, Clin Invest Med 1989; 12:357).
Issue 1173 · January 5, 2004
Alfuzosin (Uroxatral) -- Another Alpha1-blocker for Benign Prostatic Hyperplasia

Alfuzosin hydrochloride ( Uroxatral - Sanofi-Synthelabo) is now available in the US in a new formulation for once-daily treatment of benign prostatic hyperplasia (BPH). The drug has been used in Europe since…

Med Lett Drugs Ther. 2004 Jan 5; 46(1173):1-2
Alfuzosin hydrochloride ( Uroxatral - Sanofi-Synthelabo) is now available in the US in a new formulation for once-daily treatment of benign prostatic hyperplasia (BPH). The drug has been used in Europe since 1987. Alpha 1 -blockers cause relaxation of smooth muscle tone in the bladder neck, prostatic capsule and prostatic urethra, relieving symptoms of urinary obstruction.
Issue 1172 · December 22, 2003
Tadalafil (Cialis) for Erectile Dysfunction

Tadalafil ( Cialis - Lilly Icos) is the third oral drug to be approved by the FDA for treatment of erectile dysfunction. It has a longer duration of action than sildenafil ( Viagra ) or vardenafil ( Levitra -…

Med Lett Drugs Ther. 2003 Dec 22; 45(1172):101-2
Tadalafil ( Cialis - Lilly Icos) is the third oral drug to be approved by the FDA for treatment of erectile dysfunction. It has a longer duration of action than sildenafil ( Viagra ) or vardenafil ( Levitra - Medical Letter 2003; 45:77 ).
Issue 1166 · September 29, 2003
Vardenafil (Levitra) for Erectile Dysfunction

Vardenafil (Levitra -Bayer) is the second oral drug approved by the FDA for treatment of erectile dysfunction. Sildenafil (Viagra - Medical Letter 1998; 40:51), the first oral drug, has been available for 5…

Med Lett Drugs Ther. 2003 Sep 29; 45(1166):77-8
Vardenafil (Levitra -Bayer) is the second oral drug approved by the FDA for treatment of erectile dysfunction. Sildenafil (Viagra - Medical Letter 1998; 40:51), the first oral drug, has been available for 5 years. Pharmacokinetics, effectiveness, adverse effects, dosage and cost of the new drug are reviewed. Whether it offers any benefits over sildenafil is discussed.
Issue 11 · July 1, 2003
Drugs for Psychiatric Disorders

The number of drugs marketed for psychiatric indications has increased sharply in recent years. The recommendations in this article are based on the results of controlled trials and on the experience and…

Treat Guidel Med Lett. 2003 Jul; 1(11):69-76
The number of drugs marketed for psychiatric indications has increased sharply in recent years. The recommendations in this article are based on the results of controlled trials and on the experience and opinions of Medical Letter consultants. Interactions with other drugs can be found in The Medical Letter Handbook of Adverse Drug Interactions, 2003 .
Issue 1134 · July 8, 2002
Drugs That May Cause Psychiatric Symptoms

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously…

Med Lett Drugs Ther. 2002 Jul 8; 44(1134):59-62
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.
Issue 1057 · July 16, 1999
Amprenavir: A New HIV Protease Inhibitor

Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least…

Med Lett Drugs Ther. 1999 Jul 16; 41(1057):63-6
Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least four years old.
Issue 1056 · July 2, 1999
Drug Interactions

Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.

Med Lett Drugs Ther. 1999 Jul 2; 41(1056):59-62
Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.